$Affimed NV (AFMD.US)$ NEWS Affimed Announces Acceptance of ...
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
455Followers
65Following
2895Visitors
Follow